Skyrizi and Aortic aneurysm - a phase IV clinical study of FDA data

Summary:

Aortic aneurysm is reported as a side effect among people who take Skyrizi (risankizumab-rzaa), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Eliquis, and have Psoriasis.

The phase IV clinical study analyzes which people have Aortic aneurysm when taking Skyrizi. It is created by eHealthMe based on reports of 45,344 people who have side effects when taking Skyrizi from the FDA, and is updated regularly.

What is Skyrizi?

Skyrizi has active ingredients of risankizumab-rzaa. eHealthMe is studying from 45,385 Skyrizi users. Check the latest studies of Skyrizi.

What is Aortic aneurysm?

Aortic aneurysm (enlargement of an aortic artery caused by a weakening of the artery wall) is found to be associated with 751 drugs and 834 conditions by eHealthMe. Check the latest studies of Aortic aneurysm.

On Jun, 17, 2026

45,344 people reported to have side effects when taking Skyrizi.
Among them, 41 people (0.09%) have Aortic aneurysm.

Among these 41 people:

How long have people been on Skyrizi when they have Aortic aneurysm? *

What is the gender of people who have Aortic aneurysm when taking Skyrizi? *

female: 30 %
male: 70 %

What is the age of people who have Aortic aneurysm when taking Skyrizi? *

What are other drugs people take besides Skyrizi? *

Soriatane: 3 people, 7.32%
Methotrexate: 3 people, 7.32%
Diprosone: 3 people, 7.32%
Eliquis: 3 people, 7.32%
Vitamin D3: 1 person, 2.44%
Fluoxetine: 1 person, 2.44%
Aspirin: 1 person, 2.44%
Coreg: 1 person, 2.44%
Cyclobenzaprine Hydrochloride: 1 person, 2.44%
Flomax: 1 person, 2.44%

What are other side effects people have besides Aortic aneurysm? *

Diarrhea: 6 people, 14.63%
Dehydration (dryness resulting from the removal of water): 3 people, 7.32%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 7.32%
Oedema Peripheral (superficial swelling): 3 people, 7.32%
Insomnia (sleeplessness): 3 people, 7.32%
Post Procedural Complication: 3 people, 7.32%
Autoimmune Hepatitis: 2 people, 4.88%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 2 people, 4.88%
Injection Site Swelling: 2 people, 4.88%
Injection Site Bruising: 2 people, 4.88%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 29 people, 70.73%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 7 people, 17.07%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 4 people, 9.76%
High Blood Cholesterol: 2 people, 4.88%
Thrombosis (formation of a blood clot inside a blood vessel): 1 person, 2.44%
Stress And Anxiety: 1 person, 2.44%
Prostatic Disorder: 1 person, 2.44%
Nervous System Disorder (a general class of medical conditions affecting the nervous system): 1 person, 2.44%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 2.44%
High Blood Pressure: 1 person, 2.44%

* Approximation only. Some reports may have incomplete information.

Do you take Skyrizi and have Aortic aneurysm?

- Check whether Aortic aneurysm is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Skyrizi:

Skyrizi (45,385 reports)

Aortic aneurysm treatments and more:

Aortic aneurysm (10,466 reports)

Browse all side effects of Skyrizi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Aortic aneurysm:

Aortic aneurysm (751 drugs)

Browse all the conditions that are associated with Aortic aneurysm:

Aortic aneurysm (834 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on risankizumab-rzaa (the active ingredients of Skyrizi) and Skyrizi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.